EGFR and non-small cell lung carcinoma: In 30 patients with NSCLC harboring HER2 exon 20 mutations (primarily insertions) treated with the irreversible EGFR/HER2/HER4 inhibitor dacomitinib, 3 partial responses were seen [102].